Dallas, Texas 04/14/2014 (FINANCIALSTRENDS) – ImmunoGen,Inc (NASDAQ:IMGN) the cancer drug maker is breaking new stock market crests, following the initial positive results of its cancer drug- IMGN853.
Following the announcement of these results on April 8, 2014, this is one cancer drug maker who has hit high points of 8% and more.
The current phase of research studies is concentrated on the dosage of IMGN853. It has since revealed that clinical activity which had peaked when the dosage had increased to 3.3mg/Kg.
Dosage change leads to higher efficacy
The premise with the dosage was related to the ideal body weight rather than the total body weight. By following this dosage format, the blood would continue to hold concentration of IMGN853. The proposal by the company is to find more data in terms of the ‘candidate’ in the following months.
ImmunoGen, Inc. (NASDAQ:IMGN) has since begun the evaluation of IMGN853 Phase 3 study which looks at treating folate receptor alpha or FRalpha-postive cancers, of such types as endometrial, ovarian as well as lung cancer.
Pipeline is good
ImmunoGen, Inc. (NASDAQ:IMGN) has with this initial success posted good pipeline of product. In addition to IMGN853, it will also look at IMGN529, which is a non-Hodgkin Lymphoma. Other drugs include IMGN289, which includes treatment for other forms of cancer.
ImmunoGen, Inc. (NASDAQ:IMGN) is essential a cancer drug developer, where the emphasis is on the antibody-drug conjugate technology or ADC.
Peer review satisfying
Following, the presentation of the drug, for peer review at the American Association for Cancer Research or AACR Annual Meeting in San Diego, CA, it also showed findings that the New Dose Approach will help the company to achieve several objectives.
According to Dr. Charles Morris, Executive Vice President and Chief Development Officerat ImmunoGen, “Key to drug development is establishing the dosing strategy that provides the greatest efficacy with the least toxicity for each compound, and we believe the findings reported today reflect a strong path forward for IMGN853. We look forward to sharing additional IMGN853 clinical data in the months ahead.”